Drug firm Allergan is to sell its generics unit to Teva Pharmaceutical Industries in a deal worth $40.5 billion.
Drug firm Allergan is to sell its generics unit to Teva Pharmaceutical Industries in a deal worth $40.5 billion. The Israeli firm is the world’s largest maker of generic drugs and Allergan’s business is said to be a better fit for the firm that that of Mylan, which had been a target. Reuters says that Teva has now ended its pursuit of Mylan.
